Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market 2020-2030 by Category, Service Type (CMO, CRO), Therapeutic Application, End User, and Region

December 2020 | 194 pages | ID: G7B668A89B3CEN
GMD Research

Abstracts

Global pharmaceutical CDMO market will reach $289.2 billion by 2030, growing by 6.9% annually over 2020-2030 driven by increasing demand for biological therapies and specialty medicines, rising demand for cost control in drug development, and rising healthcare expenditures.

Highlighted with 96 tables and 86 figures, this 194-page report “Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market 2020-2030 by Category, Service Type (CMO, CRO), Therapeutic Application, End User, and Region” is based on a comprehensive research of the entire global pharmaceutical CDMO market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces

The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global pharmaceutical CDMO market in every aspect of the classification from perspectives of Category, Service Type, Therapeutic Application, End User, and Region.

Based on Category, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Pharmaceutical Industry
• Biopharmaceutical Industry

Based on Service Type, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Pharmaceutical Contract Manufacturing Organization (CMO)

• Active Pharmaceutical Ingredients (API) (further split into Branded API Manufacturing and Generic API Manufacturing)
• Finished Dosage Formulations (FDF) (further segmented into Solid Dosage, Oral Liquids, Parenteral/Injectables, Other FDFs)
• Secondary Packaging

Pharmaceutical Contract Research Organization (CRO)

• CRO for Pre-clinical Development
• CRO for Phase I Trials
• CRO for Phase II Trials
• CRO for Phase III Trials
• CRO for Phase IV Trials
• Laboratory Services
• Consulting Services
• Data Management Services

Based on Therapeutic Application, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Infectious Diseases
• Oncology
• Metabolic Disorders
• Cardiovascular Disorders
• Central Nervous System
• Pulmonary Disorders
• Gastrointestinal Disorders
• Other Therapeutic Applications

Based on End User, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Pharmaceutical & Biopharmaceutical Companies
• Medical Device Companies
• Academic Institutes

Geographically, the following regions together with the listed national/local markets are fully investigated:

• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Turkey, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
• North America (U.S., Canada, and Mexico)
• South America (Brazil, Chile, Argentina, Rest of South America)
• MEA (Saudi Arabia, UAE, South Africa)

For each aforementioned region and country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of all regional markets by country and split of key national markets by Category, Service Type, and Therapeutic Application over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Specifically, potential risks associated with investing in global pharmaceutical CDMO market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players (this may not be a complete list and extra companies can be added upon request):
Company Profiles of CMO:
Aenova Group
Baxter BioPharma Solutions
Boehringer Ingelheim
Catalent Inc.
Famar S.A.
Hospira, Inc.
Jubilant Life Sciences Ltd.
Lonza Group
Patheon Inc.
Pfizer CentreSource
Recipharm AB
Vetter Pharma International GmbH

Company Profiles of CRO:
Charles River Laboratories
CMIC Co. Ltd
Covance Inc.
Hangzhou Tigermed Consulting Co Ltd
ICON Plc
IQVIA Holdings Inc.
LSK Global Pharma Service Co Ltd
Novotech Pty Ltd
PAREXEL International Corporation
Pharmaceutical Product Development LLC (PPD)
PRA Health Sciences Inc.
Quanticate Ltd
Samsung Bioepis Co. Ltd
SGS SA (SGS Life Sciences)
Syneos Health Inc.
WuXi AppTec Inc.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Contents

1 INTRODUCTION

1.1 Industry Definition and Research Scope
  1.1.1 Industry Definition
  1.1.2 Research Scope
1.2 Research Methodology
  1.2.1 Overview of Market Research Methodology
  1.2.2 Market Assumption
  1.2.3 Secondary Data
  1.2.4 Primary Data
  1.2.5 Data Filtration and Model Design
  1.2.6 Market Size/Share Estimation
  1.2.7 Research Limitations
1.3 Executive Summary

2 MARKET OVERVIEW AND DYNAMICS

2.1 Market Size and Forecast
  2.1.1 Impact of COVID-19 on World Economy
  2.1.2 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis

3 SEGMENTATION OF GLOBAL MARKET BY CATEGORY

3.1 Market Overview by Category
3.2 Pharmaceutical Industry
3.3 Biopharmaceutical Industry

4 SEGMENTATION OF GLOBAL MARKET BY SERVICE TYPE

4.1 Market Overview by Service Type
4.2 Pharmaceutical Contract Manufacturing Organization (CMO)
  4.2.1 Active Pharmaceutical Ingredients (API)
  4.2.2 Finished Dosage Formulations (FDF)
  4.2.3 Secondary Packaging
4.3 Pharmaceutical Contract Research Organization (CRO)
  4.3.1 CRO for Pre-clinical Development
  4.3.2 CRO for Phase I Trials
  4.3.3 CRO for Phase II Trials
  4.3.4 CRO for Phase III Trials
  4.3.5 CRO for Phase IV Trials
  4.3.6 Laboratory Services
  4.3.7 Consulting Services
  4.3.8 Data Management Services

5 SEGMENTATION OF GLOBAL MARKET BY THERAPEUTIC APPLICATION

5.1 Market Overview by Therapeutic Application
5.2 Infectious Diseases
5.3 Oncology
5.4 Metabolic Disorders
5.5 Cardiovascular Disorders
5.6 Central Nervous System
5.7 Pulmonary Disorders
5.8 Gastrointestinal Disorders
5.9 Other Therapeutic Applications

6 SEGMENTATION OF GLOBAL MARKET BY END USER

6.1 Market Overview by End User
6.2 Pharmaceutical & Biopharmaceutical Companies
6.3 Medical Device Companies
6.4 Academic Institutes

7 SEGMENTATION OF GLOBAL MARKET BY REGION

7.1 Geographic Market Overview 2019-2030
7.2 North America Market 2019-2030 by Country
  7.2.1 Overview of North America Market
  7.2.2 U.S.
  7.2.3 Canada
  7.2.4 Mexico
7.3 European Market 2019-2030 by Country
  7.3.1 Overview of European Market
  7.3.2 Germany
  7.3.3 UK
  7.3.4 France
  7.3.5 Spain
  7.3.6 Italy
  7.3.7 Russia
  7.3.8 Rest of European Market
7.4 Asia-Pacific Market 2019-2030 by Country
  7.4.1 Overview of Asia-Pacific Market
  7.4.2 Japan
  7.4.3 China
  7.4.4 Australia
  7.4.5 India
  7.4.6 South Korea
  7.4.7 Rest of APAC Region
7.5 South America Market 2019-2030 by Country
  7.5.1 Argentina
  7.5.2 Brazil
  7.5.3 Chile
  7.5.4 Rest of South America Market
7.6 MEA Market 2019-2030 by Country
  7.6.1 UAE
  7.6.2 Saudi Arabia
  7.6.3 South Africa
  7.6.4 Other National Markets

8 COMPETITIVE LANDSCAPE

8.1 Overview of Key Vendors
8.2 New Product Launch, Partnership, Investment, and M&A
8.3 Company Profiles
  8.3.1 Company Profiles of CMO
Aenova Group
Baxter BioPharma Solutions
Boehringer Ingelheim
Catalent Inc.
Famar S.A.
Hospira, Inc.
Jubilant Life Sciences Ltd.
Lonza Group
Patheon Inc.
Pfizer CentreSource
Recipharm AB
Vetter Pharma International GmbH
  8.3.2 Company Profiles of CRO
Charles River Laboratories
CMIC Co. Ltd
Covance Inc.
Hangzhou Tigermed Consulting Co Ltd
ICON Plc
IQVIA Holdings Inc.
LSK Global Pharma Service Co Ltd
Novotech Pty Ltd
PAREXEL International Corporation
Pharmaceutical Product Development LLC (PPD)
PRA Health Sciences Inc.
Quanticate Ltd
Samsung Bioepis Co. Ltd
SGS SA (SGS Life Sciences)
Syneos Health Inc.
WuXi AppTec Inc.

9 INVESTING IN GLOBAL MARKET: RISK ASSESSMENT AND MANAGEMENT

9.1 Risk Evaluation of Global Market
9.2 Critical Success Factors (CSFs)
Related Reports and Products

List Of Tables

LIST OF TABLES

Table 1. Snapshot of Global Pharmaceutical CDMO Market in Balanced Perspective, 2019-2030
Table 2. Growth Rate of World Real GDP, 2017-2021
Table 3. World Top 10 Pharmaceutical Companies Based on Projected R&D Spending in 2026, $ bn
Table 4. Worldwide Total Number of Registered Clinical Trials
Table 5. Main Product Trends and Market Opportunities in Global Pharmaceutical CDMO Market
Table 6. Global Pharmaceutical CDMO Market by Category, 2019-2030, $ bn
Table 7. Global Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn
Table 8. Global Pharmaceutical CDMO Market: CMO by Product, 2019-2030, $ bn
Table 9. Global Pharmaceutical CDMO Market: Active Pharmaceutical Ingredients (API) by Type, 2019-2030, $ bn
Table 10. Global Pharmaceutical CDMO Market: Finished Dosage Formulations (FDF) by Type, 2019-2030, $ bn
Table 11. Global Pharmaceutical CDMO Market: CRO by Service, 2019-2030, $ bn
Table 12. Global Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn
Table 13. Global Pharmaceutical CDMO Market by End User, 2019-2030, $ bn
Table 14. Global Pharmaceutical CDMO Market by Region, 2019-2030, $ bn
Table 15. Leading National Pharmaceutical CDMO Market, 2019 and 2030, $ bn
Table 16. North America Pharmaceutical CDMO Market by Country, 2019-2030, $ bn
Table 17. U.S. Pharmaceutical CDMO Market by Category, 2019-2030, $ bn
Table 18. U.S. Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn
Table 19. U.S. Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn
Table 20. Canada Pharmaceutical CDMO Market by Category, 2019-2030, $ bn
Table 21. Canada Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn
Table 22. Canada Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn
Table 23. Mexico Pharmaceutical CDMO Market by Category, 2019-2030, $ bn
Table 24. Mexico Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn
Table 25. Mexico Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn
Table 26. Europe Pharmaceutical CDMO Market by Country, 2019-2030, $ bn
Table 27. Germany Pharmaceutical CDMO Market by Category, 2019-2030, $ bn
Table 28. Germany Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn
Table 29. Germany Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn
Table 30. UK Pharmaceutical CDMO Market by Category, 2019-2030, $ bn
Table 31. UK Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn
Table 32. UK Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn
Table 33. France Pharmaceutical CDMO Market by Category, 2019-2030, $ bn
Table 34. France Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn
Table 35. France Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn
Table 36. Spain Pharmaceutical CDMO Market by Category, 2019-2030, $ bn
Table 37. Spain Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn
Table 38. Spain Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn
Table 39. Italy Pharmaceutical CDMO Market by Category, 2019-2030, $ bn
Table 40. Italy Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn
Table 41. Italy Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn
Table 42. Russia Pharmaceutical CDMO Market by Category, 2019-2030, $ bn
Table 43. Russia Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn
Table 44. Russia Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn
Table 45. Pharmaceutical CDMO Market in Rest of Europe by Country, 2019-2030, $ bn
Table 46. APAC Pharmaceutical CDMO Market by Country, 2019-2030, $ bn
Table 47. Japan Pharmaceutical CDMO Market by Category, 2019-2030, $ bn
Table 48. Japan Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn
Table 49. Japan Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn
Table 50. China Pharmaceutical CDMO Market by Category, 2019-2030, $ bn
Table 51. China Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn
Table 52. China Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn
Table 53. Australia Pharmaceutical CDMO Market by Category, 2019-2030, $ bn
Table 54. Australia Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn
Table 55. Australia Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn
Table 56. India Pharmaceutical CDMO Market by Category, 2019-2030, $ bn
Table 57. India Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn
Table 58. India Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn
Table 59. South Korea Pharmaceutical CDMO Market by Category, 2019-2030, $ bn
Table 60. U.S. Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn
Table 61. U.S. Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn
Table 62. Pharmaceutical CDMO Market in Rest of APAC by Country, 2019-2030, $ bn
Table 63. South America Pharmaceutical CDMO Market by Country, 2019-2030, $ bn
Table 64. Argentina Pharmaceutical CDMO Market by Category, 2019-2030, $ bn
Table 65. Argentina Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn
Table 66. Argentina Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn
Table 67. Brazil Pharmaceutical CDMO Market by Category, 2019-2030, $ bn
Table 68. Brazil Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn
Table 69. Brazil Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn
Table 70. Chile Pharmaceutical CDMO Market by Category, 2019-2030, $ bn
Table 71. Chile Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn
Table 72. Chile Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn
Table 73. MEA Pharmaceutical CDMO Market by Country, 2019-2030, $ bn
Table 74. UAE Pharmaceutical CDMO Market by Category, 2019-2030, $ bn
Table 75. UAE Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn
Table 76. UAE Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn
Table 77. Saudi Arabia Pharmaceutical CDMO Market by Category, 2019-2030, $ bn
Table 78. Saudi Arabia Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn
Table 79. Saudi Arabia Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn
Table 80. South Africa Pharmaceutical CDMO Market by Category, 2019-2030, $ bn
Table 81. South Africa Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn
Table 82. South Africa Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn
Table 83. Breakdown of Global CMO Market by Key Vendor, 2019, %
Table 84. Breakdown of Global CRO Market by Key Vendor, 2019, %
Table 85. Aenova Group: Company Snapshot
Table 86. Aenova Group: Business Segmentation
Table 87. Aenova Group: Product Portfolio
Table 88. Aenova Group: Revenue, 2016-2018, $ bn
Table 89. Aenova Group: Recent Developments
Table 90. Charles River Laboratories: Company Snapshot
Table 91. Charles River Laboratories: Business Segmentation
Table 92. Charles River Laboratories: Product Portfolio
Table 93. Charles River Laboratories: Revenue, 2016-2018, $ bn
Table 94. Charles River Laboratories: Recent Developments
Table 95. Risk Evaluation for Investing in Global Market, 2019-2030
Table 96. Critical Success Factors and Key Takeaways

List Of Figures

LIST OF FIGURES

Figure 1. Research Method Flow Chart
Figure 2. Breakdown of Primary Research
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 4. Global Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030
Figure 5. Global Pharmaceutical CDMO Market, 2019-2030, $ bn
Figure 6. Impact of COVID-19 on Business
Figure 7. Primary Drivers and Impact Factors of Global Pharmaceutical CDMO Market
Figure 8. Primary Restraints and Impact Factors of Global Pharmaceutical CDMO Market
Figure 9. Investment Opportunity Analysis
Figure 10. Porter’s Fiver Forces Analysis of Global Pharmaceutical CDMO Market
Figure 11. Breakdown of Global Pharmaceutical CDMO Market by Category, 2019-2030, % of Revenue
Figure 12. Global Addressable Market Cap in 2020-2030 by Category, Value ($ bn) and Share (%)
Figure 13. Global Pharmaceutical CDMO Market: Pharmaceutical Industry, 2019-2030, $ bn
Figure 14. Global Pharmaceutical CDMO Market: Biopharmaceutical Industry, 2019-2030, $ bn
Figure 15. Breakdown of Global Pharmaceutical CDMO Market by Service Type, 2019-2030, % of Sales Revenue
Figure 16. Global Addressable Market Cap in 2020-2030 by Service Type, Value ($ bn) and Share (%)
Figure 17. Global Pharmaceutical CDMO Market: Pharmaceutical Contract Manufacturing Organization (CMO), 2019-2030, $ bn
Figure 18. Global Pharmaceutical CDMO Market: Active Pharmaceutical Ingredients (API), 2019-2030, $ bn
Figure 19. Global Pharmaceutical CDMO Market: Finished Dosage Formulations (FDF), 2019-2030, $ bn
Figure 20. Global Pharmaceutical CDMO Market: Secondary Packaging, 2019-2030, $ bn
Figure 21. Global Pharmaceutical CDMO Market: Pharmaceutical Contract Research Organization (CRO), 2019-2030, $ bn
Figure 22. Global Pharmaceutical CDMO Market: CRO for Pre-clinical Development, 2019-2030, $ bn
Figure 23. Global Pharmaceutical CDMO Market: CRO for Phase I Trials, 2019-2030, $ bn
Figure 24. Global Pharmaceutical CDMO Market: CRO for Phase II Trials, 2019-2030, $ bn
Figure 25. Global Pharmaceutical CDMO Market: CRO for Phase III Trials, 2019-2030, $ bn
Figure 26. Global Pharmaceutical CDMO Market: CRO for Phase IV Trials, 2019-2030, $ bn
Figure 27. Global Pharmaceutical CDMO Market: Laboratory Services, 2019-2030, $ bn
Figure 28. Global Pharmaceutical CDMO Market: Consulting Services, 2019-2030, $ bn
Figure 29. Global Pharmaceutical CDMO Market: Data Management Services, 2019-2030, $ bn
Figure 30. Breakdown of Global Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, % of Sales Revenue
Figure 31. Global Addressable Market Cap in 2020-2030 by Therapeutic Application, Value ($ bn) and Share (%)
Figure 32. Global Pharmaceutical CDMO Market: Infectious Diseases, 2019-2030, $ bn
Figure 33. Global Pharmaceutical CDMO Market: Oncology, 2019-2030, $ bn
Figure 34. Global Pharmaceutical CDMO Market: Metabolic Disorders, 2019-2030, $ bn
Figure 35. Global Pharmaceutical CDMO Market: Cardiovascular Disorders, 2019-2030, $ bn
Figure 36. Global Pharmaceutical CDMO Market: Central Nervous System, 2019-2030, $ bn
Figure 37. Global Pharmaceutical CDMO Market: Pulmonary Disorders, 2019-2030, $ bn
Figure 38. Global Pharmaceutical CDMO Market: Gastrointestinal Disorders, 2019-2030, $ bn
Figure 39. Global Pharmaceutical CDMO Market: Other Therapeutic Applications, 2019-2030, $ bn
Figure 40. Breakdown of Global Pharmaceutical CDMO Market by End User, 2019-2030, % of Revenue
Figure 41. Global Addressable Market Cap in 2020-2030 by End User, Value ($ bn) and Share (%)
Figure 42. Global Pharmaceutical CDMO Market: Pharmaceutical & Biopharmaceutical Companies, 2019-2030, $ bn
Figure 43. Global Pharmaceutical CDMO Market: Medical Device Companies, 2019-2030, $ bn
Figure 44. Global Pharmaceutical CDMO Market: Academic Institutes, 2019-2030, $ bn
Figure 45. Global Market Snapshot by Region
Figure 46. Geographic Spread of Worldwide Pharmaceutical CDMO Market, 2019-2030, % of Sales Revenue
Figure 47. Global Addressable Market Cap in 2020-2030 by Region, Value ($ bn) and Share (%)
Figure 48. North American Pharmaceutical CDMO Market, 2019-2030, $ bn
Figure 49. Breakdown of North America Pharmaceutical CDMO Market by Country, 2019 and 2030, % of Revenue
Figure 50. Contribution to North America 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%)
Figure 51. U.S. Pharmaceutical CDMO Market, 2019-2030, $ bn
Figure 52. Canada Pharmaceutical CDMO Market, 2019-2030, $ bn
Figure 53. Pharmaceutical CDMO Market in Mexico, 2015-2030, $ bn
Figure 54. European Pharmaceutical CDMO Market, 2019-2030, $ bn
Figure 55. Breakdown of European Pharmaceutical CDMO Market by Country, 2019 and 2030, % of Revenue
Figure 56. Contribution to Europe 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%)
Figure 57. Pharmaceutical CDMO Market in Germany, 2019-2030, $ bn
Figure 58. Pharmaceutical CDMO Market in UK, 2019-2030, $ bn
Figure 59. Pharmaceutical CDMO Market in France, 2019-2030, $ bn
Figure 60. Pharmaceutical CDMO Market in Spain, 2019-2030, $ bn
Figure 61. Pharmaceutical CDMO Market in Italy, 2019-2030, $ bn
Figure 62. Pharmaceutical CDMO Market in Russia, 2019-2030, $ bn
Figure 63. Pharmaceutical CDMO Market in Rest of Europe, 2019-2030, $ bn
Figure 64. Asia-Pacific Pharmaceutical CDMO Market, 2019-2030, $ bn
Figure 65. Breakdown of APAC Pharmaceutical CDMO Market by Country, 2019 and 2030, % of Revenue
Figure 66. Contribution to APAC 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%)
Figure 67. Pharmaceutical CDMO Market in Japan, 2019-2030, $ bn
Figure 68. Pharmaceutical CDMO Market in China, 2019-2030, $ bn
Figure 69. Pharmaceutical CDMO Market in Australia, 2019-2030, $ bn
Figure 70. Pharmaceutical CDMO Market in India, 2019-2030, $ bn
Figure 71. Pharmaceutical CDMO Market in South Korea, 2019-2030, $ bn
Figure 72. Pharmaceutical CDMO Market in Rest of APAC, 2019-2030, $ bn
Figure 73. South America Pharmaceutical CDMO Market, 2019-2030, $ bn
Figure 74. Breakdown of South America Pharmaceutical CDMO Market by Country, 2019 and 2030, % of Revenue
Figure 75. Contribution to South America 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%)
Figure 76. Pharmaceutical CDMO Market in Argentina, 2019-2030, $ bn
Figure 77. Pharmaceutical CDMO Market in Brazil, 2019-2030, $ bn
Figure 78. Pharmaceutical CDMO Market in Chile, 2019-2030, $ bn
Figure 79. Pharmaceutical CDMO Market in Rest of South America, 2019-2030, $ bn
Figure 80. Pharmaceutical CDMO Market in Middle East and Africa (MEA), 2019-2030, $ bn
Figure 81. Breakdown of MEA Pharmaceutical CDMO Market by Country, 2019 and 2030, % of Revenue
Figure 82. Contribution to MEA 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%)
Figure 83. Pharmaceutical CDMO Market in UAE, 2019-2030, $ bn
Figure 84. Pharmaceutical CDMO Market in Saudi Arabia, 2019-2030, $ bn
Figure 85. Pharmaceutical CDMO Market in South Africa, 2019-2030, $ bn
Figure 86. Growth Stage of Global Pharmaceutical CDMO Industry over the Forecast Period

COMPANIES MENTIONED

Key Players (this may not be a complete list and extra companies can be added upon request):
Company Profiles of CMO:
Aenova Group
Baxter BioPharma Solutions
Boehringer Ingelheim
Catalent Inc.
Famar S.A.
Hospira, Inc.
Jubilant Life Sciences Ltd.
Lonza Group
Patheon Inc.
Pfizer CentreSource
Recipharm AB
Vetter Pharma International GmbH
  8.3.2 Company Profiles of CRO:
Charles River Laboratories
CMIC Co. Ltd
Covance Inc.
Hangzhou Tigermed Consulting Co Ltd
ICON Plc
IQVIA Holdings Inc.
LSK Global Pharma Service Co Ltd
Novotech Pty Ltd
PAREXEL International Corporation
Pharmaceutical Product Development LLC (PPD)
PRA Health Sciences Inc.
Quanticate Ltd
Samsung Bioepis Co. Ltd
SGS SA (SGS Life Sciences)
Syneos Health Inc.
WuXi AppTec Inc.